These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study. Hobbs T; Caso R; McMahon D; Nymark M Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367 [TBL] [Abstract][Full Text] [Related]
23. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Ward N; Sahebkar A; Banach M; Watts G Curr Opin Lipidol; 2017 Dec; 28(6):495-501. PubMed ID: 28858885 [TBL] [Abstract][Full Text] [Related]
24. Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study. Toth PP; Patti AM; Nikolic D; Giglio RV; Castellino G; Biancucci T; Geraci F; David S; Montalto G; Rizvi A; Rizzo M Front Pharmacol; 2015; 6():299. PubMed ID: 26779019 [TBL] [Abstract][Full Text] [Related]
25. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Marazzi G; Campolongo G; Pelliccia F; Quattrino S; Vitale C; Cacciotti L; Massaro R; Volterrani M; Rosano G Am J Cardiol; 2017 Sep; 120(6):893-897. PubMed ID: 28781026 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. Gonnelli S; Caffarelli C; Stolakis K; Cuda C; Giordano N; Nuti R Curr Ther Res Clin Exp; 2015 Dec; 77():1-6. PubMed ID: 26649075 [TBL] [Abstract][Full Text] [Related]
27. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505 [TBL] [Abstract][Full Text] [Related]
28. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Johnston TP; Korolenko TA; Pirro M; Sahebkar A Pharmacol Res; 2017 Jun; 120():219-225. PubMed ID: 28408313 [TBL] [Abstract][Full Text] [Related]
30. Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Puato M; Zambon A; Nardin C; Faggin E; Pesavento R; Spinazzè A; Pauletto P; Rattazzi M Cardiovasc Ther; 2021; 2021():5546800. PubMed ID: 33976708 [TBL] [Abstract][Full Text] [Related]
31. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Affuso F; Ruvolo A; Micillo F; Saccà L; Fazio S Nutr Metab Cardiovasc Dis; 2010 Nov; 20(9):656-61. PubMed ID: 19699071 [TBL] [Abstract][Full Text] [Related]
32. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan. Patti AM; Katsiki N; Nikolic D; Al-Rasadi K; Rizzo M Angiology; 2015 May; 66(5):416-21. PubMed ID: 25037700 [TBL] [Abstract][Full Text] [Related]
33. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Schachter M Cardiovasc Drugs Ther; 2005 Dec; 19(6):415-22. PubMed ID: 16453091 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D; Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001 [TBL] [Abstract][Full Text] [Related]
35. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson TA Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969 [TBL] [Abstract][Full Text] [Related]
36. Role of Nutraceuticals in Hypolipidemic Therapy. Barbagallo CM; Cefalù AB; Noto D; Averna MR Front Cardiovasc Med; 2015; 2():22. PubMed ID: 26664894 [TBL] [Abstract][Full Text] [Related]
37. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]
38. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Mendoza S; Gamez R; Mas R; Goicochea E Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189 [TBL] [Abstract][Full Text] [Related]
39. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. Wong ND; Chuang J; Zhao Y; Rosenblit PD J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670 [TBL] [Abstract][Full Text] [Related]